Lupin's shares increased by 21.51% over the past year. However, year-to-date (YTD), the stock has decreased by 14.21%. Over ...

Mumbai: Global pharma major Lupin Limited has announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the ...

The Indian Pharmaceutical Alliance (IPA) has proposed reducing the import duty on pharma products from the US to zero.

Mumbai: Global pharma major Lupin Limited has announced its inclusion in prestigious S&P Global Sustainability Yearbook 2025, ...

Lupin announced that it has launched Rivaroxaban tablets USP, 2.5 mg, in the US market following final approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug ...

This follows the final approval from the US FDA for its abbreviated new drug application (ANDA). Shares of Lupin Ltd ended at ...

Lupin secures a place in the prestigious S&P Global Sustainability Yearbook 2025: Our Bureau, Mumbai Thursday, February 27, 2025, 15:45 Hrs [IST] Global pharma major Lupin Limited ...

Ramesh Swaminathan, Executive Director, Global CFO, and Head of Corporate Affairs at Lupin, noted that India's pharmaceutical industry has diversified beyond the US.

Earlier this year, Lupin’s S&P Global ESG scores moved to 76 from 69 last year, above the industry average of 30 in the pharmaceuticals sector. Lupin Limited is a global pharmaceutical leader ...

Lupin has launched Rivaroxaban Tablets USP, 2.5 mg, following the final approval of its Abbreviated New Drug Application from the U.S. FDA.

In light of uncertainties surrounding US tariffs on pharmaceuticals, Kotak Institutional Equities noted in a recent report that the most likely scenario (for both companies and investors ...